MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.25 USD
-0.06 (-1.81%)
Updated Apr 18, 2024 02:23 PM ET
After-Market: $3.32 +0.07 (2.15%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum C VGM
Price, Consensus and EPS Surprise
MEIP 3.25 -0.06(-1.81%)
Will MEIP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MEIP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MEIP
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
MEIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
Other News for MEIP
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (AvastinĀ®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma prioritizes voruciclib, will not continue with 2nd ROC
MEI Pharma reports data from study evaluating ME-344/Avastin combo for mCRC
MEI Pharma shelves plans for a second return of capital